NT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

2614 US0P

ATTORNEY'S DOCKET NUMBER

U.S. APPLICATION NO. (If known, see 37 CFR 1.5

INTERNATIONAL APPLICATION NO. PCT/JP00/03879

INTERNATIONAL FILING DATE June 15, 2000

PRIORITY DATE CLAIMED June 16, 1999

TITLE OF INVENTION

Benzazepine Derivative, Production and Use Thereof

APPLICANT(S)	FOR	DO	/FO	TIC
	1 010	ν		\mathbf{v}

Mitsuru SHIRAISHI, Masanori BABA, Yoshio ARAMAKI, Naoyuki KANZAKI, Osamu NISHIMURA

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

- 1. X This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. X A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is attached hereto (required only if not communicated by the International Bureau). has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US).
- 6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - is attached hereto.
 - b. has been previously submitted under 35 U.S.C. 154(d)(4).
- 7. X Amendments to the claims of the International Aplication under PCT Article 19 (35 U.S.C. 371(c)(3))
 - are attached hereto (required only if not communicated by the International Bureau).
 - have been communicated by the International Bureau.
 - have not been made; however, the time limit for making such amendments has NOT expired.
 - have not been made and will not be made.
- 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
- 9. X An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
- 10. An English lanugage translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

- An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 11. X
- 12. **X** An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
- 13. **X** A FIRST preliminary amendment.
- A SECOND or SUBSEQUENT preliminary amendment. 14.
- 15. A substitute specification.
- 16. A change of power of attorney and/or address letter.
- A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 1.825. 17.
- A second copy of the published international application under 35 U.S.C. 154(d)(4). 18.
- A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 19.
- 20. Other items or information:

Copy of ISR and copies of Cited References

Express Mail Label No. EL 916492262 US

Copies of Forms 210 (ISR), 301, 304, 308, 332, and PCT/RO/101 Date of Deposit 12/12/01

Translation Cover Sheet, Copy of Front Page of International Appln., Itemized Return Postcard

page I of 2

H

Ō

W

N


<u>ا</u>ظ

NJ

₽å

Stpress Marl # EC 916\$9226

U.S. APPLICATION NO AT know		NTERNATIONAL APPLICATION NO. PCT/JP00/03879		ATTORNEY'S DOCKET NUMBER 2614 USOP				
21. The follow	ing fees are submitted:			CAI	ALCULATIONS PTO USE ONLY			
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):								
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1040.00								
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO\$890.00								
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO								
International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)								
International preliminary examination fee (37 CFR 1.482) paid to USPTO								
and all claims satisfied provisions of PCT Article 33(1)-(4)			\$	890.00				
Surcharge of \$130.00 for furnishing the oath or declaration later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(e)).			\$					
CLAIMS *	NUMBER FILED	NUMBER EXTRA	RATE	\$		<u>-</u>		
Total claims	37 - 20 =	17	x \$18.00	\$	306.00			
Independent claims	3 -3 =	0	x \$84.00	\$	0			
MULTIPLE DEPEN	DENT CLAIM(S) (if ap	plicable)	+ \$280.00	\$				
	TOTAL (OF ABOVE CALCU	LATIONS =	\$	1,196.00			
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$				
SUBTOTAL =		J BTOTAL =	\$	1,196.00				
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(f)).			\$					
TOTAL NATIONAL FEE =			\$	1,196.00				
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +			\$					
TOTAL FEES ENCLOSED =			\$	1,196.00				
*After entry of Preliminary Amendment			Amount to be refunded:		\$			
				L	charged:	\$		
a. A check in the amount of \$ to cover the above fees is enclosed. b. Please charge my Deposit Account No. 500799 in the amount of \$ 1.196.00 to cover the above fees. A duplicate copy of this sheet is enclosed.								
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No500799 A duplicate copy of this sheet is enclosed.								
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.								
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.								
SEND ALL CORRESPO	ONDENCE TO:		Elen		m 7			
Elaine M	Elaine M. Ramesh, PhD, JD SIGNATURE			<u> </u>				
Takeda	Pharmaceuticals	North America, Inc	. Elaine	Elaine M. Ramesh, PhD, JD				
	0, 475 Half Day R	•	NAME					
	•		4	43,032				
	LITICOITISTILE, IL 00009 USA							
(047)303-3372 lax (047)303-340			ustomer No. 23,115					



JC13 Rec'd PCT/PTO 1 2 DEC 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

tba

Art Unit:

tba

Filed:

tba

Examiner:

tba

1st Inventor:

Mitsuru SHIRAISHI

Allowed:

For:

Benzazepine Derivative, Production and Use Thereof

Batch:

Atty. Dkt. No.

2614 US0P

1

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

USPS EXPRESS MAIL LABEL. No. EL 916492262 US

DATE IN:

December 12, 2001

Itemized Papers/Items:

- 1. This Postcard (1 page) and Certificate of Express Mailing (2 pages)
- 2. Transmittal Letter for Filing under 35 USC 371 (2 pages X 2)
- Copy of Request form of the International Application PCT/JP00/03879, (Form 3. PCT/RO/101)(5 pages)
- English Translation of the International Application as filed in Japanese [This includes 4. Specification total 550 pages, including Claims 1-37 (9 pages), Abstract (1 page)] and transmittal (1 page)
- 5. Preliminary Amendment (15 pages)k
- Information Disclosure Statement (1 page) with Form PTO-1449 (1 page), and copies of 6. references (3)
- 7. Copy of Forms PCT/IB/301, 304, 308 and 332 (4 pages)
- Copy of the front page of the International Application as published (WO 00/76993) (1 8. page)
- 9. Declaration and Power of Attorney (5 pages)
- 10. Assignment (2 pages) and Assignment Recordation cover Sheet (1 page X 2)
- 11. Copy of International Search Report (2 pages)

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

BOX PCT

Commissioner for Patents Washington, D.C. 20231.

on this date, 12/12/01

Dated: /2//2/01